SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

MicroCloud Hologram, Inc. engages in research, development, and application of holographic technology. It operates through the Holographic Solutions and Holographic Technology Service segments. The company was founded in 2020 and is headquartered in New York, NY.

MicroCloud Hologram Inc

MicroCloud Hologram Inc. is trending due to significant price volatility, sparking intense debate among investors. The community is split between those hoping for a rebound and those warning of potential dilution or a pump and dump scheme. Discussions also include the company's financials, Bitcoin holdings and quantum computing prospects.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto "crow with knife" ($CAW.X) is gaining traction, with community members actively chanting "caw caw" and highlighting its presence on multiple chains like Solana, Ethereum, and BNB. Discussion centers around its fully circulated supply, organic community growth, and unique burn mechanism. Some users suggest it's the only option in the meme coin space.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as investors anticipate its upcoming earnings report, with community discussions focused on forward guidance and potential market reactions. Several analysts have recently raised price targets, citing strong AI-driven demand and memory pricing, while others caution the stock may be priced for perfection. The broader context involves Micron's role in the semiconductor industry and its exposure to technology end markets.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as community members discuss a potential short squeeze and speculate about new government contracts following news of a partnership with SMX to enhance maritime awareness for the U.S. Navy. Investors are closely watching key resistance levels, with many drawing comparisons to Palantir and anticipating significant long-term growth in the AI-driven defense sector. Recent price action and high trading volume have fueled bullish sentiment, although some caution about potential pullbacks and the company's financials.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu ($SHI.X) is trending amid community anticipation of an imminent breakout, fueled by strong accumulation signals and a tightening chart pattern. Bulls appear to be in control, citing consistent higher lows and increasing demand outweighing supply. Some users suggest the token could be the next big community-driven run.

Bollinger Innovations Inc. operates as an electric vehicle company, which engages in the manufacture of passenger electric vehicles and commercial vehicles. It operates through the Bollinger and Mullen/ELMS segments. The company was founded by David Michery on April 20, 2010 and is headquartered in Brea, CA.

Bollinger Innovations Inc.

Bollinger Innovations Inc

BINI is trending due to a recent reverse stock split, sparking intense debate about the company's future and potential for a short squeeze. The community is split between those hoping for a reversal and those anticipating further decline, with many citing past reverse splits and dilution concerns. Discussions also include the CEO and potential partnerships in the EV sector.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as investors react to the news of a significant $245 million defense contract, viewing it as a potential catalyst for growth. The community is weighing the impact of this contract on the company's future, particularly its capacity to meet demand and its strategic position within the antimony market. Some are drawing parallels to other companies that have secured similar government contracts, while also keeping an eye on potential short squeezes.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending as investors discuss potential hyperscale deals and the company's strategic positioning in the AI data center space, with some anticipating significant price appreciation. Community members are actively debating entry points, potential partnerships with major tech players, and the impact of broader market factors on the stock. The stock's movement is also being compared to sector peers like IREN and WULF.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending as investors react to its addition to the S&P Telecom Select Industry Index and a recent $3.5 million order for ground robotics. Community members are actively discussing the company's growth potential in the defense sector and its strategic acquisitions. Some traders are noting heavy options activity and expressing optimism about the stock's near-term prospects, while others highlight the importance of securing larger contracts to justify its valuation.

Super League Enterprise, Inc. creates innovative and immersive entertainment experiences, platform and audience monetization and dynamic content feeding channels across the world’s top gaming platforms. Fueled by an insatiable desire to stay on the forefront of this ever-evolving meta landscape, Super League pioneer's proprietary digital solutions provide unparalleled access to the global gaming audience. It also creates vibrant in-game communities through the development of innovative experiences and custom content, delivering powerful opportunities for brands and advertisers to achieve impactful insights, and marketing outcomes with audiences of all ages. The company was founded by John C. Miller, David Steigelfest, and Brett Morris on October 1, 2014 and is headquartered in Santa Monica, CA.

Super League Enterprise Inc

Fueled by a recent equity investment from Evo Fund, Super League Enterprise Inc. ($SLE) is trending as traders discuss its potential to eliminate debt and meet Nasdaq requirements. Community members are noting the stock's momentum and low float, while also pointing to potential dilution concerns. Overall, the conversation revolves around the immediate impact of the investment and speculation about future catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU

Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.

NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up

Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.

REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?

Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.

Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?

Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.

Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that its experimental therapy significantly reduced symptoms of cat and birch allergies in late-stage trials, successfully meeting their key endpoints.In the <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.regeneron.com/news-releases/news-release-details/regeneron-advances-allergy-pipeline-two-positive-phase-3-trials">trials</a>, patients with moderate to severe cat or birch allergies received direct instillation of either cat dander or birch pollen into the eyes, followed by a single subcutaneous administration of the allergen-blocking antibodies. The antibody blockers “significantly reduced” allergy symptoms compared to placebo, the company said.The company stated that the data from the studies will be presented at an upcoming medical conference and used to inform confirmatory late-stage trials. Both the cat and birch allergy programs are part of a broader allergy pipeline, which includes an ongoing study in adults with severe food allergy. Initial results from the food allergy trial have been encouraging, the company said on Monday.Regeneron Chief Scientific Officer George D. Yancopoulos stated on Monday that the company anticipates significant relief at the earliest assessment time point, which is expected to last over three months, in both our cat and birch allergy programs.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REGN">REGN stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels. Shares of the company traded 1% higher in the pre-market session at the time of writing.Yancopoulos said that while millions suffer from the effects of allergies, most undergo allergy desensitization shots, often with disappointing results.“The purpose of these burdensome allergy shots is to try to build up allergen-blocking antibodies in the body. We wondered whether we could instead manufacture and directly provide allergen-blocking antibodies,” he said. “These recent Phase 3 allergen challenge trials, together with our earlier Phase 2 trials, provide compelling evidence that our first-in-class approach can have the potential to provide profound allergy relief – rapidly and durably after a single treatment – decreasing ocular, nasal and even asthma measures.”Regeneron noted that Birch pollen is one of the most common seasonal allergens in the U.S., affecting more than 10 million people, while cat allergy affects more than 20 million people. In the trials, patients received a combination of two antibody blockers or a placebo. Those who received the combination had fewer allergy symptoms, such as conjunctival redness.While additional late-stage trials in cat allergy are planned to begin in the first half of 2026, further late-stage development in birch allergy is expected to commence by the end of the year.REGN stock is down by 20% this year and by about 50% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/echostar-to-dell-17-billion-in-spectrum-assets-to-spacex/chwWH3JRdAD">EchoStar To Sell $17B In Spectrum Assets To SpaceX – Stock Rockets 40% Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Get updates to this developing story <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-experimental-therapy-reduced-symptoms-of-cat-birch-allergies-in-studies/chwWH37RdAw">directly on Stocktwits.</a>

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Regeneron Says Experimental Therapy Reduced Symptoms Of Cat, Birch Allergies In Late-Stage Trials

The company said that the antibody blockers “significantly reduced” allergy symptoms compared to a placebo in the trials. 

Equity

The company said that the antibody blockers “significantly reduced” allergy symptoms compared to a placebo in the trials. 


RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress 

Roche posts strong new data for Vabysmo in eye disease, with extended dosing and vision gains driving growth.

SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study

Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.

Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline

Merck advances growth with phase III pipeline backed by positive data for its potential first oral PCSK9 inhibitor.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

$BBAI

$BETR

$OPEN

$IONQ

Which of these trending stocks are you most bullish on for the next 5 years?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$9.67	--	--	N/A
Q2 '25	$8.43	$12.89	52.89%	BEAT
Q1 '25	$8.62	$8.22	-4.66%	MISSED
Q4 '24	$11.35	$12.07	6.37%	BEAT
Q3 '24	$11.69	$12.46	6.54%	BEAT

REGN
Regeneron Pharmaceuticals, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest REGN News

REGN Regeneron Pharmaceuticals, Inc.